Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue in an efficient manner.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue in an efficient manner.
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Hoba Therapeutics
Seed Round in 2016
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Battersea Biotech
Seed Round in 2016
Battersea Biotech develops alternative cell types and technologies to overcome the shortcomings of current CAR-T and TCR technologies.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.
Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.